APPILI THERAPEUTICS INC-CL A (APLI.CA)

Company Profile

Appili Therapeutics, Inc. is a pharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia and currently employs 7 full-time employees. The company went IPO on 2019-06-25. The firm is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.

Company Info

APPILI THERAPEUTICS INC-CL A

#21-1344 Summer Street

Halifax NOVA SCOTIA B3H 0A8

P: 19024424655

CEO: Armand Balboni

Employees: 7

Website: https://appilitherapeutics.com/